OBJECTIVE: Phase III clinical trials for depression enroll participants with major depressive disorder according to stringent inclusion and exclusion criteria. These patients may not be representative of typical depressed patients seeking treatment. This analysis used data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project--which used broad inclusion and minimal exclusion criteria--to evaluate whether phase III clinical trials recruit representative depressed outpatients. METHOD:Of 2,855 participants, 22.2% met typical entry criteria for phase III clinical trials (efficacy sample) and 77.8% did not (nonefficacy sample). These groups were compared regarding baseline sociodemographic and clinical features and the characteristics and outcomes of acute-phase treatment. RESULTS: The efficacy sample had a shorter average duration of illness and lower rates of family history of substance abuse, prior suicide attempts, and anxious and atypical symptom features. Despite similar medication dosing and time at exit dose, the efficacy participants tolerated citalopram better. They also had higher rates of response (51.6% versus 39.1%) and remission (34.4% versus 24.7%). These differences persisted even after adjustments for baseline differences. CONCLUSIONS: Phase III trials do not recruit representative treatment-seeking depressed patients. Broader phase III inclusion criteria would increase the generalizability of results to practice, potentially reducing placebo response and remission rates (reducing the risk of failed trials) but at the risk of some increase in adverse events.
RCT Entities:
OBJECTIVE: Phase III clinical trials for depression enroll participants with major depressive disorder according to stringent inclusion and exclusion criteria. These patients may not be representative of typical depressedpatients seeking treatment. This analysis used data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project--which used broad inclusion and minimal exclusion criteria--to evaluate whether phase III clinical trials recruit representative depressed outpatients. METHOD: Of 2,855 participants, 22.2% met typical entry criteria for phase III clinical trials (efficacy sample) and 77.8% did not (nonefficacy sample). These groups were compared regarding baseline sociodemographic and clinical features and the characteristics and outcomes of acute-phase treatment. RESULTS: The efficacy sample had a shorter average duration of illness and lower rates of family history of substance abuse, prior suicide attempts, and anxious and atypical symptom features. Despite similar medication dosing and time at exit dose, the efficacy participants tolerated citalopram better. They also had higher rates of response (51.6% versus 39.1%) and remission (34.4% versus 24.7%). These differences persisted even after adjustments for baseline differences. CONCLUSIONS: Phase III trials do not recruit representative treatment-seeking depressedpatients. Broader phase III inclusion criteria would increase the generalizability of results to practice, potentially reducing placebo response and remission rates (reducing the risk of failed trials) but at the risk of some increase in adverse events.
Authors: Mayumi Okuda; Deborah S Hasin; Mark Olfson; Sharaf S Khan; Edward V Nunes; Ivan Montoya; Shang-Min Liu; Bridget F Grant; Carlos Blanco Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Diane Warden; Madhukar H Trivedi; Tracy L Greer; Edward Nunes; Bruce D Grannemann; Viviana E Horigian; Eugene Somoza; Kolette Ring; Tiffany Kyle; José Szapocznik Journal: Contemp Clin Trials Date: 2011-09-17 Impact factor: 2.226
Authors: Roy H Perlis; Rudolf Uher; Michael Ostacher; Joseph F Goldberg; Madhukar H Trivedi; A John Rush; Maurizio Fava Journal: Arch Gen Psychiatry Date: 2010-12-06
Authors: Mark Zimmerman; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian; Heather L Clark Journal: CNS Drugs Date: 2016-03 Impact factor: 5.749
Authors: Bruno R Barros; Alexander Schacht; Michael Happich; Foula Televantou; Lovisa Berggren; Daniel J Walker; Hector J Dueñas Journal: Prim Care Companion CNS Disord Date: 2014-10-02
Authors: Angela M Bengtson; Brian W Pence; Bradley N Gaynes; E Byrd Quinlivan; Amy D Heine; Julie K OʼDonnell; Heidi M Crane; W Christopher Mathews; Richard D Moore; Daniel Westreich; Conall OʼCleirigh; Katerina Christopoulos; Matthew J Mimiaga; Michael J Mugavero Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Ira M Lesser; Hector F Myers; Keh-Ming Lin; Consuelo Bingham Mira; Nataria T Joseph; Natasha T Olmos; Jonathan Schettino; Russell E Poland Journal: Depress Anxiety Date: 2010 Impact factor: 6.505